Health care stocks were steady premarket Monday, with the Health Care Select Sector SPDR Fund (XLV) up a slight 0.1% and the iShares Biotechnology ETF (IBB) recently inactive.
Merck (MRK) shares were up nearly 2% after the company said two phase 3 hyperlipidemia studies showed that enlicitide decanoate led to statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol compared with placebo and other oral non-statin therapies.
NewAmsterdam Pharma (NAMS) shares were more than 13% higher after the company said obicetrapib significantly reduced plasma biomarkers associated with Alzheimer's disease in a phase 3 trial.
Axsome Therapeutics (AXSM) shares were down more than 2% after the company said it received a refuse to file letter from the US Food and Drug Administration for its new drug application for AXS-14 in fibromyalgia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.